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Abstract 
 
 
Context: Seizures are a recognised complication of acute overdose with the racemic 
(1:1 ratio of R- and S-enantiomers) selective serotonin reuptake inhibitor 
antidepressant citalopram.  
Objective: We tested the hypothesis that escitalopram (the therapeutically active S-
enantiomer of citalopram) causes fewer seizures in overdose than citalopram at 
comparable doses of the S-enantiomer.  
Methods: Multicentre retrospective review of cases with citalopram and escitalopram 
overdose reported to German, Austrian and Swiss Poisons Centres between 1997-
2006.  
Results: 316 citalopram and 63 escitalopram cases were analysed. Somnolence, 
nausea, vomiting, tachycardia, QT-prolongation and tremor occurred with similar 
frequency in both groups. There was a striking difference in the frequency of single 
and multiple seizures: 43 cases (13.5%) in the citalopram group, 1 case (1.6%) with a 
single seizure in the escitalopram group (p=0.0065).  
Discussion and conclusions: At comparable ingested doses of the S-enantiomer the 
symptom profile for citalopram and escitalopram intoxications is similar except for 
seizures which occur more frequently in citalopram than in escitalopram poisoning. 
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Introduction 
 
Citalopram (1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro[2]benzofuran-
5-carbonitrile) is a selective serotonin reuptake inhibitor (SSRI) which was introduced 
in 1991 for the treatment of depression, panic disorders and obsessive-compulsive 
disorder (Ref: Product Information). Citalopram consists of a 1:1 racemic mixture of 
the S-(+)- and R-(-)-enantiomers and the therapeutic dosage is usually 20-60 
mg/day. In comparison with citalopram the inhibition of serotonin reuptake is twice as 
high for escitalopram (the therapeutically active S-enantiomer) which was introduced 
in 2001.1 Accordingly, the therapeutic dose of escitalopram is approximately half the 
dose of citalopram, usually 10-20 mg/day. Studies comparing the therapeutic effect in 
major depressive disorder have suggested that escitalopram at an equipotent dose 
(20 mg/day) may have some clinical benefits over citalopram at full dose (40 
mg/day), such as a better MADRS score decrease (Montgomery-Asberg Depression 
Rating Scale),2 and lower drop-outs.3  
 
Information on overdoses with citalopram and escitalopram is limited. Seizures, ECG 
changes such as prolonged QT intervals and sinus tachycardia have been described 
in studies with citalopram overdose.4,5,6 In contrast, a study with 28 cases involving 
accidental or intentional overdose of escitalopram found that no patient developed 
adverse sequelae.7 In another study the most frequent symptoms were neurological 
(drowsiness, dizziness, agitation and tremor), followed by gastrointestinal (vomiting 
and nausea) and cardiovascular (tachycardia).8 Ho et al.9 described seizures and QT 
prolongation as the most serious symptoms with citalopram and escitalopram 
overdose.  
 
Since seizures and ECG changes have been observed at doses of ≥600 mg in 
citalopram overdose5 one would expect a similar profile of symptoms in escitalopram 
overdose at a dose of around 300 mg under the assumption that the therapeutically 
active enantiomer is responsible for these effects. However, a recent paper 
suggested that seizures are more common in citalopram than escitalopram 
overdose.10 This observation is consistent with anecdotal evidence from escitalopram 
overdoses reported to the Swiss Toxicological Information Centre where no seizures 
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were recorded. We therefore designed a multicentric study to evaluate the profile of 
symptoms in escitalopram and citalopram overdose and to test the hypothesis that 
escitalopram causes fewer seizures in overdose than citalopram at comparable 
doses of the S-enantiomer.  
 
 
Methods 
 
The study was designed as a multicentre retrospective review of cases with 
citalopram and escitalopram overdose reported between January 1997 and 
December 2006 to Poisons Centres in Germany (Berlin, Bonn, Erfurt, Freiburg, 
Mainz, Munich, Göttingen), Austria (Vienna) and Switzerland (Zurich). The centres 
were asked to provide the anonymised data in a standardised11 exchange spread 
sheet format. Data (age, sex, ingested drug and dose, symptoms, causality, 
decontamination measures, latency to decontamination and outcome) were entered 
by physicians blinded to the hypothesis of the present study. All cases were reviewed 
by a physician at the Swiss Toxicological Information Centre (STIC) before they were 
entered into the study to ensure that they met the inclusion criteria. Since not all 
centres classify severity of symptoms in the same way the cases were also re-
evaluated according to the Poisoning Severity Score (PSS) developed by the 
European Association of Poison Centres and Clinical Toxicologists, the International 
Programme on Chemical Safety and the European Commission.12 
 
Inclusion criteria 
 
The following criteria had to be met for reported cases to be included in the study:  
- Monointoxication with either citalopram or escitalopram; 
- follow up, reported by the treating physician, for an observation period of at 
least 6 hours after the ingestion;  
- patient age ≥ 16 yr; 
- ingested dose known within a limit of +/- 10%; 
- a likely causal relationship between overdose and clinical effect. This 
assessment was based on a clear temporal relationship between drug 
ingestion and intoxication symptoms, absence of other drugs or diseases that 
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could explain the symptoms, and a transitory nature of the symptoms. Since 
these criteria could not be used for asymptomatic patients, these cases were 
judged according to the ingestion dose reported by the patient or by relatives. 
 
Data classification 
 
According to the PSS, the severity of symptoms of individual patients was classified 
as ‘minor’ if only minor symptoms were present, as ‘moderate’ if at least one 
moderate symptom developed, and as ‘severe’ if at least one severe symptom was 
observed. A summary of symptoms according to their severity is shown in Table 1. 
 
Statistical evaluation 
 
The statistical evaluation was performed with StatView (SAS Institute Inc. Cary N. C., 
Version 5.0.1). The doses of citalopram (S-enantiomer) and escitalopram were 
compared using the unpaired Student's t-test. Chi-square analysis was used to test 
for frequency of symptoms. A p<0.05 (two-way) was considered statistically 
significant. 
 
 
Results 
 
During the study period (January 1997-December 2006) a total of 316 cases with 
citalopram monointoxication and 63 escitalopram monointoxications that fulfilled all 
inclusion criteria were reported from the following centres: Berlin (13 cases with 
citalopram/1 case with escitalopram), Bonn (22/4), Erfurt (24/3), Freiburg (40/2), 
Göttingen (3/-), Mainz (84/8), Munich (5/1), Vienna (-/16) and Zurich (125/28). 
 
The demographic characteristics of patients in the citalopram and escitalopram 
groups were similar with both groups showing a predominance of females and a 
mean age of just over 30 years (Table 2). The ingested citalopram doses ranged 
from 80 mg to 4200 mg (mean 712 mg corresponding to 356 mg of the S-
enantiomer). For escitalopram, the dose range was 40 mg to 1860 mg (mean 322 
mg). There was no significant difference between ingested doses of the S-
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enantiomer in the citalopram and escitalopram group (p=0.49), both overall and in the 
individual severity categories. In both groups the severity of symptoms was related to 
the ingested dose (Table 3). However, the distribution of cases within the severity 
categories was different between the two groups, with escitalopram showing 
proportionally more asymptomatic cases, and no cases with severe symptoms. 
 
The reported symptoms and their severity classification are shown in Table 4. 
Somnolence was by far the most frequently reported symptom for both citalopram 
and escitalopram intoxications (43.7% and 40.0%, respectively). Other common 
symptoms such as nausea and vomiting, tachycardia, QT-prolongation and tremor 
also occurred with similar frequency in both groups. However, there was a striking 
difference in the frequency of single and multiple seizures: 43 cases (14%) were 
seen in the citalopram group and only 1 case (2%) with a single seizure was reported 
in the escitalopram group (Table 5). Accordingly, seizures were the most frequent 
symptom determining moderate (48.5% of symptoms) and severe outcomes (83.3% 
of symptoms) in the citalopram group, but not the escitalopram group (10.0% of 
moderate symptoms and no severe outcomes). 
 
The dose range in which seizures were seen was 280-4200 mg (mean 1568 mg, 
corresponding to 784 mg of S-enantiomer) for citalopram versus 1860 mg for the 
single escitalopram case. In the citalopram group the lowest dose at which a seizure 
occurred was 140 mg S-enantiomer (280 mg citalopram) followed by 2 cases with 
200 mg S-enantiomer (400 mg citalopram). Overall in the citalopram group seizures 
were seen at doses of 200-400 mg S-enantiomer in 8 of 73 cases (11%); at doses of 
401-600 mg S-enantiomer in 11 of 41 cases (27%); at doses of 601-800 mg S-
enantiomer in 7 of 17 cases (41%) and in the higher dose range (>800 mg) in 14 of 
27 cases (52%). 
 
Gastric lavage and activated charcoal were used for gastrointestinal 
decontamination. In 37 (11.7 %) patients with citalopram overdose and in 6 (9.5%) 
patients with escitalopram overdose gastrointestinal decontamination was performed 
within one hour. In 149 (47.2 %) citalopram and 21 (33.3 %) escitalopram cases no 
decontamination was performed or it was performed later than 1h after ingestion. In 
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130 (41.1%) cases with citalopram ingestion and in 36 (57.2 %) cases with 
escitalopram ingestion no information on decontamination was provided (Table 2). 
 
 
Discussion 
 
This study compares the clinical symptoms and dose response relationship in 316 
patients with citalopram and 63 patients with escitalopram overdose. It was designed 
to test the hypothesis that escitalopram causes fewer seizures in overdose than 
citalopram at comparable doses of the S-enantiomer. 
 
The demographic characteristics of patients in the citalopram and escitalopram 
groups were similar. There was no significant difference between ingested doses of 
the S-enantiomer in the citalopram and escitalopram groups. The fact that the 
frequency of somnolence, vomiting, tachycardia, QT-prolongation and tremor was 
similar in the citalopram and escitalopram groups would also suggest that the 
ingested doses were of similar potency in terms of overall toxicity profile. However, 
we found a striking difference in the frequency of seizures with 14% in the citalopram 
group versus 2% in the escitalopram group. Despite the difference in group size this 
result was statistically significant. 
 
The symptoms of citalopram overdose in our study were similar to those described in 
the literature. Seizures, prolonged QT intervals and sinus tachycardia have been 
described in a study with five patients who took up to 5200 mg of citalopram.4 A 
review of 44 patients with citalopram overdose ≥ 600 mg showed seizures and ECG 
changes.5 In this study the frequency of patients developing seizures was 14%, an 
almost identical result to our investigation.  
 
Information in the literature on symptoms following escitalopram overdose is very 
limited. Lo Vecchio et al.7 found no seizures in a retrospective chart review of 28 
patients with escitalopram overdose. In another study8 with 1179 cases of 
escitalopram ingestion the most frequently observed adverse effects were 
neurological (drowsiness, dizziness, agitation and tremor), followed by 
gastrointestinal (vomiting and nausea) and cardiovascular (tachycardia). Seizures 
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were observed in 3 cases (0.3%). Van Gorp et al.13 describe serotonin toxicity, QT 
prolongation and bradycardia as major manifestations of escitalopram overdose. No 
seizures were observed in this study including 79 patients. 
Recently the first study comparing the toxicity of citalopram versus escitalopram in 
overdose was published.10 Most frequently reported clinical effects with citalopram 
and escitalopram were tachycardia, drowsiness, hypertension, and vomiting. 
Seizures (8% vs. 0.2%, respectively) and tremor (8.6% vs. 3.1%, respectively) were 
more common with citalopram. In a congress presentation of a study with 228 
patients with citalopram and 33 patients with escitalopram overdose, seizures and 
QT prolongation were the most serious symptoms. In this study 17 cases (7.5%) with 
seizures were seen in the citalopram group and 1 case (3%) in the escitalopram 
group.9  
 
The lowest dose that caused seizures in our citalopram case series was 280 mg 
(corresponding to 140 mg S-enantiomer). There is little information in the literature 
concerning a dose response for seizures in overdose. Two authors mention 400 
mg10,14 and two authors 600 mg or more4,5 as the minimal dose for seizures. The 
difference between these doses and that seen in our study may be related to the 
smaller number of cases compared to our study.  
The only patient developing seizures in our study ingested 1860 mg escitalopram, 
which is considerably higher than the 300 mg described in the single case of seizures 
observed by Hayes et al.10 
 
Our study was not designed to investigate the reasons for the difference of the two 
substances with regard to the development of seizures in overdose. Seizures are 
caused by an imbalance between excitatory and inhibitory influences. Thus, 
epileptogenesis can arise if excitatory transmission is facilitated or inhibitory 
transmission is reduced. GABAB receptors, serotonin receptors and histamine H1 
receptors have all been reported to have some role in this process.15,16,17,18 However, 
data for citalopram and escitalopram suggest that there is no difference in receptor 
affinity for serotonin and GABAB in comparable doses of the S-enantiomer. With 
regard to serotonin reuptake transporter (SERT) occupancy, Klein et al.19 reported no 
significant difference when comparing administration of an equivalent single dose of 
escitalopram and the S-enantiomer of citalopram. However, a higher SERT 
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occupancy in midbrain was found after multiple dose administration of 10 mg/day 
escitalopram compared to 20 mg/day citalopram. These results may be explained by 
an attenuating effect of R-citalopram on the occupancy of S-citalopram at the 
serotonin transporters.20 Hyttel and Sanchez found no difference in GABAB receptor 
affinity between R- and S-enantiomer.1,21 However, the fact that the R-enantiomer of 
citalopram has some affinity for H1 receptors suggests the possibility of a lowering of 
inhibitory influences over histamine receptors.1 Among other neurotransmitters, 
histamine has been described to have a role in the inhibition of seizures via H1 
histamine receptors.18 Thus, the H1 antagonistic effect of the R-enantiomer could 
possibly impair anticonvulsant activity. 
 
Apart from serotonin, histamine and GABAB receptors there are other possible 
mechanisms for seizures. However, Jobe22 showed that noradrenergic influences do 
not account for the proconvulsant properties of antidepressant drugs.  
The glycine receptor (GlyR) is one of the major inhibitory receptors in the adult 
mammalian central nervous system. Inhibition at the glycine receptor might play a 
significant role in SSRI-associated seizures,23 but no information in the literature 
could be found regarding the affinity of the R- and S-citalopram enantiomers for this 
receptor. 
 
G protein-activated inwardly rectifying K+ (GIRK) channels also play an important role 
in the inhibitory regulation of neuronal excitability in most brain regions through 
activation of various G protein coupled receptors.24 It has been suggested that the 
inhibition of neuronal GIRK channels may contribute to the occurrence of seizures in 
overdose with citalopram.25 However, there is no comparative study on inhibition of 
GIRK channels by R- and S-citalopram.  
 
Interpretation of our findings is limited by the retrospective nature of the study design. 
In addition, our strict inclusion/exclusion criteria, in particular the decision to only 
include monointoxications and cases with a known ingested dose led to small case 
numbers especially in the escitalopram group. However, we felt that these restrictions 
were necessary in order to be able to interpret the findings, in particular since we 
were not able to obtain confirmation of the ingested dose by measuring serum 
concentrations of citalopram and escitalopram. Comparing the dose of escitalopram 
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with that of the racemic mixture citalopram is hampered by the lack of information on 
the clinical effect of the R-enantiomer. However, for the reasons stated above and 
from a clinician’s point of view we believe it is justified to compare the therapeutically 
active moieties rather than the amount of chemical substance. 
 
 
Conclusions 
 
In conclusion, our findings add substantial weight to previous suggestions that 
citalopram is more likely to cause seizures than escitalopram in overdose at 
comparable doses of the S-enantiomer. The reasons for this difference are currently 
unclear but may be related to a lowering of inhibitory influences on histamine 
receptors by the R-enantiomer of citalopram. This may make escitalopram a safer 
drug in overdose, but it is important to confirm our findings in a prospective study, 
and to investigate the possible mechanisms for this difference. 
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Table 1. Symptoms and severity of intoxication 
 
 
 Minor Moderate Severe 
 
Nervous system 
 
Somnolence, 
dizziness, tremor, 
restlessness, 
drowsiness, tinnitus, 
ataxia, mild 
anticholinergic 
symptoms (dry 
mouth, mydriasis) 
 
 
Unconsciousness with 
appropriate response to 
pain (GCS* 8-9), 
agitation, single 
generalized or local 
seizures, myoclonia 
 
Deep coma with 
inappropriate 
response to pain 
or unresponsive 
to pain (GCS ≤7), 
multiple 
generalized 
seizures 
Cardiovascular 
system 
Mild ECG changes 
(QTc† >390ms ♂, 
>440ms ♀; extra 
systoles, right 
bundle branch 
block) 
Tachycardia (100-
139 bpm) 
 
Moderate ECG changes 
(QTc >430ms ♂, 
>485ms ♀; AV block I°) 
Tachycardia (140-179 
bpm) 
 
 
Gastrointestinal 
tract 
Vomiting, nausea, 
diarrhea, pain 
 
Pronounced or 
prolonged vomiting, 
diarrhea, pain, ileus, 
intestinal atonia 
 
 
 
 
*Glasgow Coma Scale; †QT interval corrected for heart rate. 
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Table 2. Patient baseline characteristics 
 
 Citalopram Escitalopram 
Number of patients 316 63 
Sex female:male:unknown (%) 74:19:7 68:27:5 
Age (years) 
- mean ± SD                       31.5 ± 14.8 32.4 ± 13.1 
- median, range 30.0, 16-84 32.5, 16-60 
Dose (mg) 
- mean 712 322 
- range 80-4200 40-1860 
- S-enantiomer 356                 322  (p=0.49) 
Decontamination 
- within 1h   37 (11.7%)   6 (9.5%) 
- >1h/no decontamination  149 (47.2%)    21 (33.3%) 
- unknown           130 (41.1%)                       36 (57.2%) 
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Table 3. Severity of symptoms and ingested dose 
 
 Citalopram (n=316) Escitalopram (n=63) 
 
Number 
of cases 
Dose (mg) 
Range, mean, mean of S-
enantiomer          
Number  
of cases 
Dose (mg) 
Range, mean         
No symptoms   53 (17%) 80-2000, 423, 211    20 (32%)  60-400, 223 
Minor                 199  (63%) 80-3920, 565, 282    35  (55%)  40-1200, 318 
Moderate 50  (16%) 100-4200, 1307, 653    8 (13%)  60-1860, 588 
Severe 14 (4%) 200-4000, 1788, 894   
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Table 4. Clinical effects 
 
  Citalopram N= 316 Escitalopram N= 63 
  Minor Moderate Severe Minor Moderate Severe
Somnolence 138  (43.7%)      25 (40 %)     
Coma - moderate (GCS* 8-9)    6 (1.9%)     1 (1.6%)   
           - severe (GCS ≤ 7)       2 (0.6%)       
Dizziness  25  (7.9%)      2 (3.1%)     
Restlessness  11  (3.5%)      2 (3.1%)     
Agitation    13 (4.1%)     4 (6.3%)   
Hallucination    3 (0.9%)         
Convulsion - simple    33 (10.4%)     1 (1.6%)   
                   - multiple     10 (3.1%)       
Other Symptoms of the nervous 
system 
(hyperreflexia, apathy, slow down, 
amnesia, speech disorder, ataxia, 
paraesthesia) 
 11  (3.5%)           
Myclonia    8 (2.5%)         
Tremor  26  (8.2%)      8 (12.7%)     
Mydriasis  21  (6.6%)      3 (4.7%)     
Tachycardia - (100-139 bpm)  53 (16.8%)      7 (11.1%)     
                    -  (140-179 bpm)    1 (0.3%)         
ECG changes  
- mild (QTc >390ms ♂, >440ms ♀, 
extra systoles, right bundle branch 
block) 
 25  (7.9%)      4 (6.3%)     
 -  moderate (QTc >430ms ♂, 
>485ms ♀)    2 (0.6%)     1 (1.6%)   
AV-Block I°    2  (0.6%)         
Nausea  32  (10.1%)      4 (6.3%)     
Vomiting   56  (17.7%)      8 (12.7%)     
Vomiting prolonged         1 (1.6%)   
Intestinal atonia         1 (1.6%)   
Urinary retention         1 (1.6%)   
 
*Glasgow Coma Scale.
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Table 5. Most frequent symptoms 
 
 Citalopram (n=316) Escitalopram (n=63) p 
Somnolence  138 (44%)   25 (40%)  0.56 
Vomiting  56 (18%)  9 (14%)  0.51 
Tachycardia  54 (17%)  7 (11%)  0.24 
Seizures  43 (14%)  1 (2%)  0.0065 
QT-prolongation        27 (9%)  5 (8%)  0.87 
Tremor  26 (8%)  8 (13%)  0.25 
 
 
P values for the comparison between the two groups of the most frequent symptoms 
are calculated using Chi-square analysis. A p<0.05 (two-way) was considered 
statistically significant. 
 
